Mode
Text Size
Log in / Sign up
Phase 4 N=80 Randomized Triple-blind Treatment

Premedication With Melatonin and Alprazolam Combination Versus Alprazolam or Melatonin Alone

Anxiety

Enrolled (actual)
80
Serious AEs
0.0%
Results posted
Oct 2012
Primary outcome: Primary: Change in VAS Anxiety Score Relative to Baseline After Premedication — 0.35; 0.70; 0.65; 0.25 Centimeter

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
meloset (melatonin) (Drug); stresnil ( melatonin and alprazolam) (Drug); (alprax) alprazolam (Drug); placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
B.P. Koirala Institute of Health Sciences
Primary completion
Jan 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in VAS Anxiety Score Relative to Baseline After Premedication
0.35; 0.70; 0.65; 0.25
PRIMARY
Change in VAS Anxiety Score Relative to Baseline at 30 Minutes After Premedication
1.15; 1.72; 1.62; 0.82
PRIMARY
Change in VAS Anxiety Score Relative to Baseline at One Hour After Premedication
1.80; 2.92; 2.35; 0.85
SECONDARY
Sedation Score at One Hour After Premedication
0.5; 1; 1; 0
SECONDARY
Orientation Score
2; 2; 2; 2
SECONDARY
Number of Patients With Intact Memory
13; 4; 5; 14
SECONDARY
Amount of Propofol Consumption
79.2; 65.5; 59.0; 75.8
SECONDARY
Number of Patients With Loss of Memory for Being Transferred to Operating Room.
1; 5; 4; 0

Summary

Background: Benzodiazepine, a common premedicant, suppresses endogenous melatonin levels and thus paradoxically increases episodes of arousal during sleep and thus causes restlessness and hangs over effects. Adding melatonin to it may decrease nocturnal arousal and promote the perception of sound sleep in the perioperative period. Methods: Eighty patients (ASA 1&2) with anxiety VAS ≥ 2 posted for general anaesthesia will be randomly assigned to receive 0.5 mg alprazolam (Group A), 3 mg melatonin, a combination of 0.5 mg alprazolam and 3 mg melatonin (Group AM), or a similar looking placebo (Group P), approximately 90 minutes before surgery.

Eligibility Criteria

Inclusion Criteria

  • (ASA 1&2),
  • aging 18 to 65 years
  • having anxiety VAS score of more than 2
  • posted for general anaesthesia with estimated duration of < 3 hours.

Exclusion Criteria

  • patients taking analgesics, sedatives, antiepileptics or antidepressants,
  • suffering from obesity (BMI ≥ 28) or neuropsychiatric disease,
  • having allergy to the study drugs
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01486615). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search